Kharma 2020.

Study name	Anticoagulation in patients suffering from COVID‐19 disease‐The Anti‐Co Trial
Starting date	28 June 2020
Contact information	Marcus Lance, MD, PhD Hamad Medical Corporation Doha, Qatar 00974 ext 33530292 | mlance@hamad.qa
Methods	Triple‐blind, 2‐armed, parallel‐assignment RCT
Participants	100 participants,  ≥ 18 years, female and male Inclusion criteria: Adult patient (≥ 18 years of age) Positive COVID‐test Under mechanical ventilation D‐dimers > 1.2 mg/L Exclusion criteria: Pregnancy Allergy to the drug (bivalirudin) Inherited coagulation abnormalities No informed consent
Interventions	Experimental: Drug: bivalirudin injection This group will receive standard anticoagulation with LMWH/UFH Drug: standard treatment The participants will receive IV bivalirudin according to the institutional HIT protocol Comparator: Standard treatment In this arm the participants will be treated according to our standard anticoagulation protocol The participants will not be treated with bivalirudin (the investigational drug)
Outcomes	Primary P/F ratio (time frame: 3 days of intervention) the P/F ratio is a surrogate parameter for oxygenation in ARDS Secondary Kidney function (time frame: 3 days of intervention) The kidney function frequently is deteriorated in COVID‐19 patients
Notes	NCT04445935 | No data provided